Gen Alpha

Business

Amgen Returns Eczema Drug Rocatinlimab to Kyowa Kirin After Phase III Success, Shifting Strategic Focus

Amgen has transferred full rights for the atopic dermatitis drug rocatinlimab back to Kyowa Kirin, clearing the path for the Japanese firm to pursue US approval by 2026. The move comes despite the drug meeting all trial endpoints, reflecting Amgen's portfolio reprioritization and a tempered market outlook for the OX40 inhibitor class.

Feb 2, 2026

World

Singapore Enters the Space Race: New National Agency Aims to Lead Southeast Asia's Ascent

Singapore has officially launched its first national space agency, positioning itself at the forefront of Southeast Asia's push to capitalize on a global space economy projected to surge to $1.8 trillion by 2035.

Feb 2, 2026

Business

Cogent Biosciences Gains Key FDA Designations for Bezuclastinib, Spotlighting GIST Treatment Potential

Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.

Feb 2, 2026

Business

HBAR's Path to Recovery: Technical Divergences Offer Hope Amidst Broken Accumulation Streak

Despite a 35% monthly plunge, Hedera's HBAR shows signs of underlying buyer interest through key technical divergences. However, a critical shift in exchange flows threatens to delay any near-term price rebound, leaving the token at a pivotal juncture.

Feb 2, 2026

Business

OpenClaw AI Agents Go On-Chain: How Autonomous Software Is Reshaping Crypto Markets

The rapid adoption of OpenClaw, an open-source autonomous AI agent platform, is moving beyond social media buzz to directly execute transactions on blockchain networks, prompting both excitement about efficiency and deep concerns over market stability and accountability.

Feb 2, 2026

Business

enGene Holdings Stock Plunge Tests Major Private Equity Backers

A sharp 16% weekly decline in enGene Holdings' share price puts significant pressure on its largest shareholder group—private equity firms controlling nearly half the company—raising questions about strategy and future direction amid broader market volatility.

Feb 2, 2026

Business

Cash Flow Alone Isn't Enough: Three High-Generating Stocks That Raise Investor Concerns

While robust cash generation is a hallmark of financial health, it doesn't guarantee stock outperformance. We examine three companies—PVH, Scorpio Tankers, and Amneal Pharmaceuticals—where strong cash flows are overshadowed by strategic challenges, raising red flags for discerning investors.

Feb 2, 2026

World

Singapore Charts New Frontier: National Space Agency to Launch Amid Global Investment Boom

Singapore will establish its National Space Agency on April 1st, aiming to leverage its technological prowess to secure a strategic position in the rapidly expanding global space economy, as global investments continue to soar.

Feb 2, 2026

Business

FDA Grants Breakthrough Status to Cogent Biosciences' GIST Combo Therapy, Accelerating Path to Market

Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.

Feb 2, 2026

Business

Waymo's $110 Billion Funding Quest Shifts Spotlight to Alphabet's Long-Term Bet

Alphabet's self-driving subsidiary Waymo is reportedly seeking a new funding round that would value the company at approximately $110 billion, drawing fresh attention to the tech giant's ambitious bets beyond its core advertising business and the evolving landscape of autonomous vehicle investment.

Feb 2, 2026

Business

Eli Lilly Doubles Down: $3.5 Billion Bet on Next-Gen Obesity Drugs and Gene Therapy Partnerships

Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.

Feb 2, 2026

Business

Alphabet's AI Momentum and Cloud Surge Fuel Optimism Ahead of Q4 Earnings

With its core search business resilient, cloud division soaring, and new AI deals like the Apple partnership taking shape, Alphabet enters its February 4 earnings report on a strong note, though regulatory and valuation concerns linger.

Feb 2, 2026

Business

Gen X's Retirement Reality Check: Average 401(k) Balance Falls Short of Comfort

New data reveals the average 401(k) balance for Generation X, painting a concerning picture for those nearing retirement. Experts weigh in on the gap and potential strategies to bridge it.

Feb 2, 2026

Business

Amgen Earnings Preview: Biotech Giant Faces Growth Test Amid Market Scrutiny

As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.

Feb 2, 2026

US

Protests Erupt in Milan Over U.S. ICE Agents' Role in 2026 Winter Olympics Security

Thousands demonstrated in Milan against the planned deployment of U.S. Immigration and Customs Enforcement (ICE) agents for the 2026 Winter Games, citing human rights concerns and viewing their presence as a symbol of democratic erosion in the United States.

Feb 2, 2026

US

ProPublica Reveals Identities of Federal Agents in Fatal Shooting of VA Nurse Alex Pretti

ProPublica has identified the two federal agents involved in the January shooting of Alex Pretti, a case marked by disputed official narratives and calls for transparency.

Feb 2, 2026

Business

Generac's Stock Surge: Is the Power Equipment Giant Still a Buy After 19% Rally?

Generac Holdings' shares have surged 19% in a month, reigniting the debate over its valuation. While recent momentum is strong, a five-year decline of 38% underscores the challenges. Analysts see a potential upside, but risks from the residential solar slowdown and data center demand volatility loom.

Feb 2, 2026

World

Argentina Taps U.S. Treasury for $808 Million in IMF Payment, Reports Say

Argentina has reportedly purchased $808 million in Special Drawing Rights from the U.S. Treasury to cover an upcoming interest payment to the International Monetary Fund, highlighting the nation's ongoing financial pressures.

Feb 2, 2026

Business

Sarepta's Gene Therapy Shows Sustained Slowing of DMD Progression in Landmark Three-Year Data

New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.

Jan 31, 2026

Business

Invesco Mortgage Capital Rides Agency Wave to Strong Q4 Finish, Eyes 2026 Momentum

Invesco Mortgage Capital (IVR) posted robust fourth-quarter results, buoyed by a calmer interest rate environment and outperformance in agency mortgage-backed securities. Executives detailed strategic portfolio positioning amid spread tightening and signaled cautious optimism for the year ahead.

Jan 31, 2026